<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:09:09 -0700</creation_date>
  <update_date>2013-01-15 19:09:09 -0700</update_date>
  <accession>HMDBP02917</accession>
  <secondary_accessions>
    <accession>8425</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>5-HT-3</synonym>
    <synonym>5-HT3-A</synonym>
    <synonym>5-HT3A</synonym>
    <synonym>5-HT3R</synonym>
    <synonym>5-hydroxytryptamine receptor 3</synonym>
    <synonym>Serotonin receptor 3A</synonym>
    <synonym>Serotonin-gated ion channel receptor</synonym>
  </synonyms>
  <gene_name>HTR3A</gene_name>
  <general_function>Involved in extracellular ligand-gated ion channel activity</general_function>
  <specific_function>This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05035</accession>
      <name>Ondansetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00259</accession>
      <name>Serotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14514</accession>
      <name>Mirtazapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14521</accession>
      <name>Palonosetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14742</accession>
      <name>Cisapride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14859</accession>
      <name>Procaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14866</accession>
      <name>Rocuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14895</accession>
      <name>Dolasetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15026</accession>
      <name>Granisetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15104</accession>
      <name>Alosetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15177</accession>
      <name>Memantine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15292</accession>
      <name>Chloroprocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15330</accession>
      <name>Tubocurarine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>11q23.1</locus>
    <gene_sequence>&gt;1437 bp
ATGCTGCTGTGGGTCCAGCAGGCGCTGCTCGCCTTGCTCCTCCCCACACTCCTGGCACAG
GGAGAAGCCAGGAGGAGCCGAAACACCACCAGGCCCGCTCTGCTGAGGCTGTCGGATTAC
CTTTTGACCAACTACAGGAAGGGTGTGCGCCCCGTGAGGGACTGGAGGAAGCCAACCACC
GTATCCATTGACGTCATTGTCTATGCCATCCTCAACGTGGATGAGAAGAATCAGGTGCTG
ACCACCTACATCTGGTACCGGCAGTACTGGACTGATGAGTTTCTCCAGTGGAACCCTGAG
GACTTTGACAACATCACCAAGTTGTCCATCCCCACGGACAGCATCTGGGTCCCGGACATT
CTCATCAATGAGTTCGTGGATGTGGGGAAGTCTCCAAATATCCCGTACGTGTATATTCGG
CATCAAGGCGAAGTTCAGAACTACAAGCCCCTTCAGGTGGTGACTGCCTGTAGCCTCGAC
ATCTACAACTTCCCCTTCGATGTCCAGAACTGCTCGCTGACCTTCACCAGTTGGCTGCAC
ACCATCCAGGACATCAACATCTCTTTGTGGCGCTTGCCAGAAAAGGTGAAATCCGACAGG
AGTGTCTTCATGAACCAGGGAGAGTGGGAGTTGCTGGGGGTGCTGCCCTACTTTCGGGAG
TTCAGCATGGAAAGCAGTAACTACTATGCAGAAATGAAGTTCTATGTGGTCATCCGCCGG
CGGCCCCTCTTCTATGTGGTCAGCCTGCTACTGCCCAGCATCTTCCTCATGGTCATGGAC
ATCGTGGGCTTCTACCTGCCCCCCAACAGTGGCGAGAGGGTCTCTTTCAAGATTACACTC
CTCCTGGGCTACTCGGTCTTCCTGATCATCGTTTCTGACACGCTGCCGGCCACTGCCATC
GGCACTCCTCTCATTGGTGTCTACTTTGTGGTGTGCATGGCTCTGCTGGTGATAAGTTTG
GCCGAGACCATCTTCATTGTGCGGCTGGTGCACAAGCAAGACCTGCAGCAGCCCGTGCCT
GCTTGGCTGCGTCACCTGGTTCTGGAGAGAATCGCCTGGCTACTTTGCCTGAGGGAGCAG
TCAACTTCCCAGAGGCCCCCAGCCACCTCCCAAGCCACCAAGACTGATGACTGCTCAGCC
ATGGGAAACCACTGCAGCCACATGGGAGGACCCCAGGACTTCGAGAAGAGCCCGAGGGAC
AGATGTAGCCCTCCCCCACCACCTCGGGAGGCCTCGCTGGCGGTGTGTGGGCTGCTGCAG
GAGCTGTCCTCCATCCGGCAATTCCTGGAAAAGCGGGATGAGATCCGAGAGGTGGCCCGA
GACTGGCTGCGCGTGGGCTCCGTGCTGGACAAGCTGCTATTCCACATTTACCTGCTAGCG
GTGCTGGCCTACAGCATCACCCTGGTTATGCTCTGGTCCATCTGGCAGTACGCTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>478</residue_number>
    <molecular_weight>55279.8</molecular_weight>
    <theoretical_pi>7.43</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>242-268</region>
      <region>274-292</region>
      <region>303-321</region>
      <region>456-475</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-23</region>
    </signal_regions>
    <protein_sequence>&gt;5-hydroxytryptamine receptor 3A
MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTT
VSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDI
LINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLH
TIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRR
RPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAI
GTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQ
STSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQ
ELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P46098</uniprot_id>
  <uniprot_name>5HT3A_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>D49394</genbank_gene_id>
  <genecard_id>HTR3A</genecard_id>
  <geneatlas_id>HTR3A</geneatlas_id>
  <hgnc_id>HGNC:5297</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Miyake A, Mochizuki S, Takemoto Y, Akuzawa S: Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol. 1995 Sep;48(3):407-16.</reference_text>
      <pubmed_id>7565620</pubmed_id>
    </reference>
    <reference>
      <reference_text>Belelli D, Balcarek JM, Hope AG, Peters JA, Lambert JJ, Blackburn TP: Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol. 1995 Dec;48(6):1054-62.</reference_text>
      <pubmed_id>8848005</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bruss M, Gothert M, Hayer M, Bonisch H: Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs.  Ann N Y Acad Sci. 1998 Dec 15;861:234-5.</reference_text>
      <pubmed_id>9928262</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bruss M, Eucker T, Gothert M, Bonisch H: Exon-intron organization of the human 5-HT3A receptor gene.  Neuropharmacology. 2000 Jan 4;39(2):308-15.</reference_text>
      <pubmed_id>10670426</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF: The 5-HT3B subunit is a major determinant of serotonin-receptor function.  Nature. 1999 Jan 28;397(6717):359-63.</reference_text>
      <pubmed_id>9950429</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dubin AE, Huvar R, D'Andrea MR, Pyati J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L, Jackson MR, Lovenberg TW, Erlander MG: The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem. 1999 Oct 22;274(43):30799-810.</reference_text>
      <pubmed_id>10521471</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kelley SP, Dunlop JI, Kirkness EF, Lambert JJ, Peters JA: A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature. 2003 Jul 17;424(6946):321-4.</reference_text>
      <pubmed_id>12867984</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cheng A, McDonald NA, Connolly CN: Cell surface expression of 5-hydroxytryptamine type 3 receptors is promoted by RIC-3. J Biol Chem. 2005 Jun 10;280(23):22502-7. Epub 2005 Apr 4.</reference_text>
      <pubmed_id>15809299</pubmed_id>
    </reference>
    <reference>
      <reference_text>Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, Bonisch H, Gothert M, Rappold G, Bruss M: Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol Pharmacol. 2007 Jul;72(1):8-17. Epub 2007 Mar 28.</reference_text>
      <pubmed_id>17392525</pubmed_id>
    </reference>
    <reference>
      <reference_text>Frank B, Niesler B, Bondy B, Spath M, Pongratz DE, Ackenheil M, Fischer C, Rappold G: Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. Clin Rheumatol. 2004 Aug;23(4):338-44. Epub 2004 May 7.</reference_text>
      <pubmed_id>15293096</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Takao H, Minabe Y, Nakatani N, Higuchi T, Detera-Wadleigh SD, Yoshikawa T: Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry. 2006 Jul 15;60(2):192-201. Epub 2006 Feb 17.</reference_text>
      <pubmed_id>16487942</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity?  J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8.</reference_text>
        <pubmed_id>10446734</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Gorman JM: Mirtazapine: clinical overview.  J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8.</reference_text>
        <pubmed_id>10446735</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4.</reference_text>
        <pubmed_id>17587360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23.</reference_text>
        <pubmed_id>8930006</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine.  CNS Drug Rev. 2001 Fall;7(3):249-64.</reference_text>
        <pubmed_id>11607047</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Hesketh PJ: New treatment options for chemotherapy-induced nausea and vomiting.  Support Care Cancer. 2004 Aug;12(8):550-4. Epub 2004 Jun 30.</reference_text>
        <pubmed_id>15232725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Grunberg SM, Koeller JM: Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003 Dec;4(12):2297-303.</reference_text>
        <pubmed_id>14640928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Rubenstein EB: Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004 May;2(5):284-9.</reference_text>
        <pubmed_id>16163194</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003 Dec 1;98(11):2473-82.</reference_text>
        <pubmed_id>14635083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Stoltz R, Cyong JC, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004 May;44(5):520-31.</reference_text>
        <pubmed_id>15102873</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>De Leon A: Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. Proc (Bayl Univ Med Cent). 2006 Oct;19(4):413-6.</reference_text>
        <pubmed_id>17106506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Yang LP, Scott LJ: Palonosetron: in the prevention of nausea and vomiting.  Drugs. 2009 Nov 12;69(16):2257-78. doi: 10.2165/11200980-000000000-00000.</reference_text>
        <pubmed_id>19852528</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Navari RM: Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.  Future Oncol. 2006 Oct;2(5):591-602.</reference_text>
        <pubmed_id>17026451</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003 Oct;14(10):1570-7.</reference_text>
        <pubmed_id>14504060</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Siddiqui MA, Scott LJ: Palonosetron.  Drugs. 2004;64(10):1125-32; discussion 1133-4.</reference_text>
        <pubmed_id>15139789</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A: Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004 Feb;15(2):330-7.</reference_text>
        <pubmed_id>14760130</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Stoltz R, Parisi S, Shah A, Macciocchi A: Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004 Nov;25(8):329-37.</reference_text>
        <pubmed_id>15378559</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Nagakura Y, Akuzawa S, Miyata K, Kamato T, Suzuki T, Ito H, Yamaguchi T: Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999 May;39(5):375-82.</reference_text>
        <pubmed_id>10328995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Talley NJ: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther. 1992 Jun;6(3):273-89.</reference_text>
        <pubmed_id>1600046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>de Ridder WJ, Schuurkes JA: Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors. J Pharmacol Exp Ther. 1993 Jan;264(1):79-88.</reference_text>
        <pubmed_id>8093733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Haga N, Suzuki H, Shiba Y, Mochiki E, Mizumoto A, Itoh Z: Effect of TKS159, a novel 5-hydroxytryptamine4 agonist, on gastric contractile activity in conscious dogs. Neurogastroenterol Motil. 1998 Aug;10(4):295-303.</reference_text>
        <pubmed_id>9697104</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Fan P, Weight FF: Procaine impairs the function of 5-HT3 receptor-ion channel complex in rat sensory ganglion neurons. Neuropharmacology. 1994 Dec;33(12):1573-9.</reference_text>
        <pubmed_id>7539114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procaine</name>
        <accession>HMDB14859</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rocuronium</name>
        <accession>HMDB14866</accession>
      </metabolite>
      <reference>
        <reference_text>Min KT, Wu CL, Yang J: Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes. Anesth Analg. 2000 Feb;90(2):476-81.</reference_text>
        <pubmed_id>10648343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Conroy T, Cappelaere P, Fabbro M, Fauser AA, Splinter TA, Spielmann M, Schneider M, Chevallier B, Goupil A, Chauvergne J, et al.: Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. Am J Clin Oncol. 1994 Apr;17(2):97-102.</reference_text>
        <pubmed_id>8141114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Reith MK, Sproles GD, Cheng LK: Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist.  Drug Metab Dispos. 1995 Aug;23(8):806-12.</reference_text>
        <pubmed_id>7493546</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003 Dec 1;98(11):2473-82.</reference_text>
        <pubmed_id>14635083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Monaca-Charley C, Stojkovic T, Duhamel A, De Seze J, Ferriby D, Vermersch P: Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol. 2003 Oct;250(10):1190-4.</reference_text>
        <pubmed_id>14586600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL: Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol. 1992 Aug 14;219(1):9-13.</reference_text>
        <pubmed_id>1397053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Balfour JA, Goa KL: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997 Aug;54(2):273-98.</reference_text>
        <pubmed_id>9257083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Hui YF, Ignoffo RJ: Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist.  Cancer Pract. 1997 Sep-Oct;5(5):324-8.</reference_text>
        <pubmed_id>9341357</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89.</reference_text>
        <pubmed_id>9506240</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38.</reference_text>
        <pubmed_id>15740177</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Hillsley K, Grundy D: Plasticity in the mesenteric afferent response to cisplatin following vagotomy in the rat. J Auton Nerv Syst. 1999 May 28;76(2-3):93-8.</reference_text>
        <pubmed_id>10412832</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Turvill JL, Connor P, Farthing MJ: The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br J Pharmacol. 2000 Jul;130(5):1031-6.</reference_text>
        <pubmed_id>10882387</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Giorgi G, Ghelardini C, Collina S: Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure: synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities. Bioorg Med Chem. 2002 Mar;10(3):779-801.</reference_text>
        <pubmed_id>11814868</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38.</reference_text>
        <pubmed_id>15740177</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.</reference_text>
        <pubmed_id>12943486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Ho KY, Gan TJ: Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006 Dec;19(6):606-11.</reference_text>
        <pubmed_id>17093363</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Abdelsayed GG: Management of radiation-induced nausea and vomiting.  Exp Hematol. 2007 Apr;35(4 Suppl 1):34-6.</reference_text>
        <pubmed_id>17379085</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Feyer P, Seegenschmiedt MH, Steingraeber M: Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26.</reference_text>
        <pubmed_id>16044252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Clayton NM, Sargent R, Butler A, Gale J, Maxwell MP, Hunt AA, Barrett VJ, Cambridge D, Bountra C, Humphrey PP: The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motil. 1999 Jun;11(3):207-17.</reference_text>
        <pubmed_id>10354345</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome.  Expert Opin Pharmacother. 2003 Nov;4(11):2089-98.</reference_text>
        <pubmed_id>14596662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Coldwell JR, Phillis BD, Sutherland K, Howarth GS, Blackshaw LA: Increased responsiveness of rat colonic splanchnic afferents to 5-HT after inflammation and recovery. J Physiol. 2007 Feb 15;579(Pt 1):203-13. Epub 2006 Nov 30.</reference_text>
        <pubmed_id>17138606</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Houghton LA, Foster JM, Whorwell PJ: Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000 Jun;14(6):775-82.</reference_text>
        <pubmed_id>10848662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Gunput MD: Review article: clinical pharmacology of alosetron.  Aliment Pharmacol Ther. 1999 May;13 Suppl 2:70-6.</reference_text>
        <pubmed_id>10429744</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Balfour JA, Goa KL, Perry CM: Alosetron.  Drugs. 2000 Mar;59(3):511-8; discussion 519-20.</reference_text>
        <pubmed_id>10776833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Camilleri M: Pharmacology and clinical experience with alosetron.  Expert Opin Investig Drugs. 2000 Jan;9(1):147-59.</reference_text>
        <pubmed_id>11060667</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Rahimi R, Nikfar S, Abdollahi M: Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008 May;30(5):884-901.</reference_text>
        <pubmed_id>18555935</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis JH: Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29.</reference_text>
        <pubmed_id>20136586</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Andresen V, Hollerbach S: Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283-92.</reference_text>
        <pubmed_id>15061683</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Memantine</name>
        <accession>HMDB15177</accession>
      </metabolite>
      <reference>
        <reference_text>Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG: The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001 Jun 22;306(1-2):81-4.</reference_text>
        <pubmed_id>11403963</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroprocaine</name>
        <accession>HMDB15292</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Hefft S, Hulo S, Bertrand D, Muller D: Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. J Physiol. 1999 Mar 15;515 ( Pt 3):769-76.</reference_text>
        <pubmed_id>10066903</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Yan D, White MM: Interaction of d-tubocurarine analogs with mutant 5-HT(3) receptors.  Neuropharmacology. 2002 Sep;43(3):367-73.</reference_text>
        <pubmed_id>12243766</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Yan D, Meyer JK, White MM: Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure. Mol Pharmacol. 2006 Aug;70(2):571-8. Epub 2006 May 24.</reference_text>
        <pubmed_id>16723497</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Peters JA, Malone HM, Lambert JJ: Antagonism of 5-HT3 receptor mediated currents in murine N1E-115 neuroblastoma cells by (+)-tubocurarine. Neurosci Lett. 1990 Mar 2;110(1-2):107-12.</reference_text>
        <pubmed_id>1691468</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Emerit MB, Riad M, Fattaccini CM, Hamon M: Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem. 1993 Jun;60(6):2059-67.</reference_text>
        <pubmed_id>7684066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
